Proliferation, C-myc, and cyclin D1 expression in diffuse alveolar damage: Potential roles in pathogenesis and implications for prognosis

Human Pathology

Volumn 30, Issue 9, 1999, Pages 1050-1057

  Adamson, Ann ^b   Perkins, Sherrie ^c   Brambilla, Elisabeth ^c   Tripp, Sheryl ^c   Holden, Joseph ^c   Travis, William ^c   Guinee Jr , Donald ^a  

^a VIRGINIA MASON MEDICAL CENTER   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c NONE

Author keywords

Acute lung injury; ARDS; C myc; Cyclin D1; Diffuse alveolar damage; DNA topoisomerase II ; Proliferation

Indexed keywords

BIOLOGICAL MARKER; CYCLIN D1; DNA TOPOISOMERASE (ATP HYDROLYSING);

ADULT; AGED; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LUNG ALVEOLUS CELL; LUNG INJURY; MALE; ONCOGENE C MYC; PATHOGENESIS; PROGNOSIS;

EID: 0032887361     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(99)90222-8     Document Type: Article

References (76)

1. Katzenstein AL, Bloor CM, Liebow AA: Diffuse alveolar damage: The role of oxygen, shock, and related factors. Am J Pathol 85:210-228, 1976
2. Kapanci Y, Tosco R, Eggermann J, et al: Oxygen pneumonitis in man: Light and electron microscopic morphometric studies. Chest 62:162-169, 1972
3. Bachofen M, Weibel ER: Basic pattern of tissue repair in human lungs following unspeciflc injury. Chest 65:14S-19S, 1974 (suppl)
4. Ashbaugh DG, Bigelow DB, Petty TL, et al: Acute respiratory distress in adults. Lancet 2:319-323, 1967
5. Blaisdell FW, Schlobohm RM: The respiratory distress syndrome: A review. Surgery 74:251-262, 1973
6. Katzenstein ALA: Acute lung injury patterns: Diffuse alveolar damage and bronchiolitis obliterans-organizing pneumonia, in Anonymous: Katzenstein and Askin's Surgical Pathology of Non-neoplastic Lung Disease. Philadelphia, PA, Saunders, 1997, pp 14-47
7. Guinee DG Jr., Fleming M, Hayashi T, et al: Association of p53 and WAF1 expression with apoptosis in diffuse alveolar damage. Am J Pathol 149:531-538, 1996
8. Bardales RH, Xie S-S, Schaefer RF, et al: Apoptosis is a major pathway responsible for the resolution of type II pneumocytes in acute lung injury. Am J Pathol 149:845-852, 1996
9. Barazzone C: Oxygen toxicity in mouse lung: Pathways to cell death. Am J Respir Cell Mol Biol 19:573-581, 1998
10. Buckley S: Apoptosis and DNA damage in type 2 alveolar epithelial cells cultured from hyperoxic rats. Am J Physiol 274:L714-L720, 1998
11. O'Reilly MA: Exposure to hyperoxia induces p53 expression in mouse lung epithelium. Am J Respir Cell Mol Biol 18:43-50, 1998
12. Kuwano K: P53 and p21 (Wafl/Cip1) mRNA expression associated with DNA damage and repair in acute immune complex alveolitis in mice. Lab Invest 76:161-169, 1997
13. O'Reilly MA: Accumulation of p21(Cip 1/WAF1) during hyperoxic lung injury in mice. Am J Respir Cell Mol Biol 19:777-785, 1998
14. Guinee D Jr., Brambilla E, Fleming M, et al: The potential role of Bax and Bcl-2 expression in diffuse alveolar damage. Am J Pathol 151:999-1007, 1997
15. Polunovsky VA, Rosenwald IB, Tan AT, et al: Translational control of programmed cell death: Eukaryotic translation initiation factor 4E blocks apoptosis in growth-factor-restricted fibroblasts with physiologically expressed or deregulated Myc. Mol Cell Biol 16:6573-6581, 1996
16. Wagner AJ, Small MB, Hay N: Myc-mediated apoptosis is blocked by ectopic expression of Bcl-2. Mol Cell Biol 13:2432-2440, 1993
17. Harrington EA, Bennett MR, Fanidi A, et al: c-myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J 13:3286-3295, 1994
18. Raff MC, Barres BA, Burne JF, et al: Programmed cell death and the control of cell survival: Lessons from the nervous system. Science 262:695-700, 1993
19. Raff MC: Social controls on cell survival and cell death. Nature 356:397-400, 1992
20. Sherr CJ: G1 phase progression: Cycling on cue. Cell 79:551-555, 1994
21. Matsushime H, Quelle DE, Shurtleff SA, et al: D-type cyclin-dependent kinase activity in mammalian cells. Mol Cell Biol 14:2066-2076, 1994
22. Lukas J, Pagano M, Staskova Z, et al: Cyclin D1 protein oscillates and is essential for cell cycle progression in human tumour cell lines. Oncogene 9:707-718, 1994
23. Quelle DE, Ashmun RA, Shurtleff SA, et al: Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev 7:1559-1571, 1993
24. Kranenburg O, van der Eb AJ, Zantema A: Cyclin D1 is an essential mediator of apoptotic neuronal cell death. EMBO J 15:46-54, 1996
25. Baldin V, Lukas J, Marcote MJ, et al: Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 7:812-821, 1993
26. Pardo FS, Su M, Borek C: Cyclin D1 induced apoptosis maintains the integrity of the G1/S checkpoint following ionizing radiation irradiation. Somat Cell Mol Genet 22:135-144, 1996
27. Han EK, Begemann M, Sgambato A, et al: Increased expression of cyclin D1 in a murine mammary epithelial cell line induces p27kip1, inhibits growth, and enhances apoptosis. Cell Growth Differ 7:699-710,1996
28. Sofer Levi Y, Resnitzky D: Apoptosis induced by ectopic expression of cyclin D1 but not cyclin E. Oncogene 13:2431-2437, 1996
29. Sakamuro D, Eviner V, Elliott KJ, et al: G-myc induces apoptosis in epithelial cells by both p53-dependent and p53-independent mechanisms. Oncogene 11:2411-2418, 1995
30. Chiarugi V, Ruggiero M: Role of three cancer "master genes" p53, bcl2 and c-myc on the apoptotic process. Tumori 82:205-209, 1996
31. Ryan KM, Birnie GD: Myc oncogenes: The enigmatic family. Biochem J 314:713-721, 1996
32. Packham G, Cleveland JL: c-Myc and apoptosis. Biochim Biophys Acta 1242:11-28, 1995
33. Drake FH, Hofmann GA, Bartus HF, et al: Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry 28:8154-8160, 1989
34. Woessner RD, Mattern MR, Mirabelli CK, et al: Proliferationand cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ 2:209-214, 1991
35. Heck MM, Earnshaw WC: Topoisomerase II: A specific marker for cell proliferation. J Cell Biol 103:2569-2581, 1986
36. Capranico G, Tinelli S, Austin CA, et al: Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development. Biochim Biophys Acta 1132:43-48, 1992
37. Juenke JM, Holden JA: The distribution of DNA topoisomerase II isoforms in differentiated adult mouse tissues. Biochim Biophys Acta 1216:191-196, 1993
38. Lynch BJ, Guinee DG Jr, Holden JA: Human DNA topoisomerase II-alpha: A new marker of cell proliferation in invasive breast cancer. HUM PATHOL 28:1180-1188, 1997
39. Holden JA, Perkins SL, Snow GW, et al: Immunohistochemical staining for DNA topoisomerase II in non-Hodgkin's lymphomas. Am J Clin Pathol 104:54-59, 1995
40. Norton AJ, Jordan S, Yeomans P: Brief, high-temperature heat denaturation (pressure cooking) : A simple and effective method of antigen retrieval for routinely processed tissues. J Pathol 173:371-379, 1994
41. Taylor CR, Shi S-R, Cote RJ: Antigen retrieval for immunohistochemistry: Status and need for greater standardization. Appl Immunohistochem 4:144-166, 1996
42. Giorno R: A comparison of two immunoperoxidase staining methods based on the avidin-biotin interaction. Diagn Immunol 2:161-166, 1984
43. King G, Payne S, Walker F, et al: A highly sensitive detection method for immunohistochemistry using biotinylated tyramine. J Pathol 183:237-241, 1997
44. Nash G, Blennerhassett JB, Pontoppidan H: Pulmonary lesions associated with oxygen therapy and artificial ventilation. N Engl J Med 276:368-374, 1967
45. Nash G, Foley FD, Langlinais PC: Pulmonary interstitial edema and hyaline membranes in adult burn patients. Electron microscopic observations. HUM PATHOL 5:149-160, 1974
46. Murray JF, Matthay MA, Luce JM, et al: An expanded definition of the adult respiratory distress syndrome [published erratum appears in Am Rev Respir Dis 139:1065, 1989. Am Rev Respir Dis 138:720-723, 1988
47. Katzenstein AL, Myers JL, Mazur MT: Acute interstitial pneumonia: A clinicopathologic, ultrastructural, and cell kinetic study. Am J Surg Pathol 10:256-267, 1986
48. Broers JL, Viallet J, Jensen SM, et al: Expression of c-myc in progenitor cells of the bronchopulmonary epithelium and in a large number of non-small cell lung cancers. Am J Respir Cell Mol Biol 9:33-43, 1993
49. Saksela K: Myc genes and their deregulation in lung cancer. J Cell Biochem 42:153-180, 1990
50. Takahashi T, Obata Y, Sekido Y, et al: Expression and amplification of myc gene family in small cell lung cancer and its relation to biological characteristics. Cancer Res 49:2683-2688, 1989
51. Jiang W, Kahn SM, Zhou P, et al: Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression. Oncogene 8:3447-3457, 1993
52. Marcu KB, Bossone SA, Patel AJ: Myc function and regulation. Annu Rev Biochem 61:809-860, 1992
53. Evan GI, Littlewood TD: The role of c-myc in cell growth. Curr Opin Genet Dev 3:44-49, 1993
54. Askew DS, Ashmun RA, Simmons BC, et al: Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 6:1915-1922, 1991
55. Prochownik EV, Kukowska J, Rodgers C: C-myc antisense transcripts accelerate differentiation and inhibit G1 progression in murine erythroleukemia cells. Mol Cell Biol 8:3683-3695, 1988
56. Heikkila R, Schwab G, Wickstrom E, et al: A c-myc antisense oligodeoxynucleotide inhibits entry into S phase but not progress from G0 to G1. Nature 328:445-449, 1987
57. Kato J, Matsushime H, Hiebert SW, et al: Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev 7:331-342, 1993
58. Dowdy SF, Hinds PW, Louie K, et al: Physical interaction of the retinoblastoma protein with human D cyclins. Cell 73:499-511, 1993
59. Meyerson M, Harlow E: Identification of G1 kinase activity for cdk6, a novel cyclin D partner. Mol Cell Biol 14:2077-2086, 1994
60. Freeman RS, Estus S, Johnson EMJ: Analysis of cell cyclerelated gene expression in postmitotic neurons: Selective induction of cyclin D1 during programmed cell death. Neuron 12:343-355, 1994
61. Evan GI, Wyllie AH, Gilbert CS, et al: Induction of apoptosis in fibroblasts by c-myc protein. Cell 69:119-128, 1992
62. Bitterman PB: Pathogenesis of fibrosis in acute lung injury. Am J Med 92:39S-43S, 1992
63. Martinet Y, Menard O, Vaillant P, et al: Cytokines in human lung fibrosis. Arch Toxicol Suppl 18:127-139, 1996
64. Liebler JM, Picou MA, Qu Z, et al: Altered immunohistochemical localization of basic fibroblast growth factor after bleomycin-induced lung injury. Growth Factors 14:25-38, 1997
65. Uhal BD, Joshi I, True AL, et al: Fibroblasts isolated after fibrotic lung injury induce apoptosis of alveolar epithelial cells in vitro. Am J Physiol 269:L819-L828, 1995
66. Polunovsky VA, Chen B, Henke C, et al: Role of mesenchymal cell death in lung remodeling after injury. J Clin Invest 92:388-397, 1993
67. Meduri GU, Chinn AJ, Leeper KV, et al: Corticosteroid rescue treatment of progressive fibroproliferation in late ARDS: Patterns of response and predictors of outcome. Chest 105:1516-1527, 1994
68. Meduri GU, Belenchia JM, Estes RJ, et al: Fibroproliferative phase of ARDS: Clinical findings and effects of corticosteroids. Chest 100:943-952, 1991
69. Evans Storms RB, Cidlowski JA: Regulation of apoptosis by steroid hormones. J Steroid Biochem Mol Biol 53:1-8, 1995
70. Thompson EB: Apoptosis and steroid hormones. Mol Endocrinol 8:665-673, 1994
71. Chen B, Polunovsky V, White J, et al: Mesenchymal cells isolated after acute lung injury manifest an enhanced proliferative phenotype. J Clin Invest 90:1778-1785, 1992
72. Frierson HF Jr, Gaffey MJ, Zukerberg LR, et al: Immunohistochemical detection and gene amplification of cyclin D1 in mammary infiltrating ductal carcinoma. Mod Pathol 9:725-730, 1996
73. Yatabe Y, Nakamura S, Seto M, et al: Clinicopathologic study of PRAD1/cyclin D1 overexpressing lymphoma with special reference to mantle cell lymphoma: A distinct molecular pathologic entity. Am J Surg Pathol 20:1110-1122, 1996
74. Chang H, Benchimol S, Minden MD, et al: Alterations of p53 and c-myc in the clonal evolution of malignant lymphoma. Blood 83:452-459, 1994
75. Garte SJ: The c-myc oncogene in tumor progression. Grit Rev Oncogene 4:435-449, 1993
76. Guinee DG Jr, Holden JA, BenfieldJR, et al: Comparison of DNA topoisomerase IIα expression in small cell and non-small cell carcinoma of the lung: In search of a mechanism of chemotherapeutic response. Cancer 78:729-735, 1996